GLP-1 medications have rapidly accelerated this challenge, becoming one of the fastest-growing and most expensive line items in employer health plans
The medication has a half-life of approximately five days, allowing for once-weekly dosing
CJC-1295 for GHRH)
Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE
Most patients with detectable anti-tirzepatide antibodies continue to experience therapeutic benefit without any noticeable symptoms, and the presence of antibodies does not automatically necessitate treatment discontinuation
The mean follow-up time among patients who started DPP4 inhibitors was 5.4 (3.5) years